U.S. Markets close in 6 hrs 13 mins

Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

EAST SETAUKET, NY--(Marketwired - Feb 3, 2016) -  Lixte Biotechnology Holdings, Inc. ( OTCQB : LIXT ) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016. 

John S. Kovach, MD, founder and president of Lixte said, "Dr. Manuel Mameli, Inserm investigator, and Dr. Salvatore Lecca in his team at Inserm Unit 839, the Institut du Fer a Moulin, have identified increased activity in a specific region of the brain in mice showing depressive symptoms after stressful experience. This hyperactivity returns to normal after a single administration of LB-100. Dr. Mameli, in a press release from Inserm (http://presse.inserm.fr/en/treating-depressive-symptoms-from-their-roots/22124/) is quoted 'Our study unravels early cellular mechanisms able to trigger complex behavioral responses. Our study further highlights the role of the lateral habenula in the aetiology of depression. Our results provide insights on a novel potential pharmacologic target that could be studied for a therapy of mood disorders.'"

Dr. Kovach continued, "We are very interested in the findings of Dr. Mameli and his team. Their observation of rapid amelioration of the depressive symptoms by LB-100 in widely used rodent models encourages us to see if these findings translate to patients with refractory depression. As Lixte recently reported, the initial clinical study of LB-100, a Phase 1 trial in cancer patients, revealed stabilization of several types of cancer without dose-limiting toxicity, with some patients receiving LB-100 for several months. We believe a proof-of-concept clinical study of LB-100 in refractory depression is warranted. Such a trial is especially attractive because, if the results of the animal studies hold true in patients, improvement in symptoms would be expected to occur in a matter of hours rather than after weeks of treatment required by most compounds available for depressive symptoms."

"It is not surprising," Dr. Kovach added, "that a 'targeted compound' such as LB-100 which has anticancer activity would potentially have activity in non-neoplastic diseases. Many cancers have acquired genetic alterations that perturb functions of the PP2A pathway while normal tissues do not. We believe the activity of LB-100 against different types of cancer in model systems results from its targeting an already genetically disturbed PP2A pathway in the cancer but not in normal cells. Mameli and colleagues have now shown that non-genetic dysregulation of PP2A activity associated with depressive-like symptoms arises in a focal region of the brain in mice exposed to acute stress, and that targeting this abnormal PP2A function with LB-100 eliminates symptoms and restores normal PP2A activity. As altered PP2A function is known to be present in other benign diseases, there are several, if not many, potential applications of PP2A modulation to be explored."

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is completing a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCTO1837667).

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml

Additional information on the Company is available at www.lixte.com.

  • Business
    Markit

    See what the IHS Markit Score report has to say about ON Semiconductor Corp.

    NASDAQ/NGS:ON Summary Bearish sentiment is low Economic output for the sector is expanding but at a slower rate Short interest | Positive Short interest is low for ON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETF/Index ownership | Neutral ETF activity is neutral.

  • Why United Technologies (UTX) Might Surprise This Earnings Season
    Business
    Zacks

    Why United Technologies (UTX) Might Surprise This Earnings Season

    Investors are always looking for stocks that are poised to beat at earnings season and United Technologies Corporation UTX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because United Technologies is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • What To Know Before Buying Dime Community Bancshares, Inc. (NASDAQ:DCOM) For Its Dividend
    Business
    Simply Wall St.

    What To Know Before Buying Dime Community Bancshares, Inc. (NASDAQ:DCOM) For Its Dividend

    Let's dig deeper into whether Dime Community Bancshares should have a place in your portfolio. checks you should use to assess a dividend stock When assessing a stock as a potential addition to my dividend Portfolio, I look at these five areas: Does it pay an annual yield higher than 75% of dividend payers? Has it consistently paid a stable dividend without missing a payment or drastically cutting payout?

  • Barrick (GOLD) Releases Preliminary Q4 Production Results
    Business
    Zacks

    Barrick (GOLD) Releases Preliminary Q4 Production Results

    Barrick Gold Corporation GOLD released preliminary production results for fourth-quarter and 2018. Preliminary gold production and sales for the fourth quarter were 1.26 million ounces and 1.23 million ounces, respectively. Gold production for 2018 was 4.53 million ounces, which was within the previous guidance of 4.5-5 million ounces.

  • Democrat who opposed Pelosi for speaker is blocked from a seat on the judiciary committee
    Politics
    Fox Business Videos

    Democrat who opposed Pelosi for speaker is blocked from a seat on the judiciary committee

    New Jersey Democrat Rep. Jeff Van Drew says he did not vote Nancy Pelosi for speaker because his constituents wanted someone with new ideas.

  • 4 Marijuana Stocks That Look Profitable in 2019
    Business
    Zacks

    4 Marijuana Stocks That Look Profitable in 2019

    While legalization of marijuana in several U.S. states and in Canada will surely help cannabis growth to hit such a promising number by 2022, a number of dispensaries have been given the permit to sell legalized cannabis. At the same time, mergers and acquisitions between large beverage, tobacco, pharma and cannabis companies should certainly help the weed market grow. After all, deal making will diversify their product portfolio and propel growth.

  • Is Dave & Buster's Entertainment Stock a Buy In 2019?
    Business
    Motley Fool

    Is Dave & Buster's Entertainment Stock a Buy In 2019?

    Comparable sales are expected to increase anywhere from 1.8% to 2.5%, although it remains to be seen if the restaurant side has turned a corner or it's the arcade segment that's responsible for keeping business afloat. The expectation for 15 to 16 new store openings in 2019 was also reiterated, which has been the sole growth driver over the last year. Rising comparable sales at existing locations added back into the mix could be a big boost for sales and profits.

  • Why Earnings Season Could Be Great for Procter & Gamble (PG)
    Business
    Zacks

    Why Earnings Season Could Be Great for Procter & Gamble (PG)

    Investors are always looking for stocks that are poised to beat at earnings season and The Procter & Gamble Company PG may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Procter & Gambleis seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • What You Must Know About SpartanNash Company's (NASDAQ:SPTN) Financial Strength
    Business
    Simply Wall St.

    What You Must Know About SpartanNash Company's (NASDAQ:SPTN) Financial Strength

    At this current level of debt, SPTN currently has US$21m remaining in cash and short-term investments , ready to deploy into the business. Additionally, SPTN has generated US$124m in operating cash flow in the last twelve months, resulting in an operating cash to total debt ratio of 18%, indicating that SPTN's operating cash is not sufficient to cover its debt. This ratio can also be a sign of operational efficiency as an alternative to return on assets.

  • Cannabis Players' Valuations: Which Stocks Look Cheap in January?
    Business
    Market Realist

    Cannabis Players' Valuations: Which Stocks Look Cheap in January?

    Cannabis Players' Valuations: Which Stocks Look Cheap in January? Valuations As we near the end of the first month of 2019, it's time to look at the valuation multiples of cannabis stocks and determine which ones look cheap.

  • Selling Maxar Stock? You Could Be Making a Huge Mistake
    Business
    Motley Fool

    Selling Maxar Stock? You Could Be Making a Huge Mistake

    Last quarter, Maxar updated investors on its capital spending plans for fiscal 2018, advising that through the end of last year, it planned to spend between $300 million and $315 million on capital improvements (mainly for a new satellite constellation dubbed "WorldView Legion"). Now, through the end of the third quarter, Maxar had spent only about one-third this amount -- $115 million. That means that when Q4 results come out, we should see a sharp spike in spending.

  • Are Investors Undervaluing FGL Holdings (FG) Right Now?
    Business
    Zacks

    Are Investors Undervaluing FGL Holdings (FG) Right Now?

    While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. Looking at the history of these trends, perhaps none is more beloved than value investing. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

  • Watch CNBC's full interview with Marriott CEO Arne Sorens...
    World
    CNBC Videos

    Watch CNBC's full interview with Marriott CEO Arne Sorens...

    Marriott International President and CEO Arne Sorenson joins "Squawk Box" at the Davos World Economic Forum to discuss the state of the travel industry, what the typical consumer wants and his response to the hacking Marriott experienced last year.

  • Archer Daniels Rides on Solid Cost Saving & Readiness Efforts
    Business
    Zacks

    Archer Daniels Rides on Solid Cost Saving & Readiness Efforts

    Archer Daniels Midland Company ADM has been in investors' good books, courtesy of various strategic efforts such as cost-savings plan, Project Readiness and reinforcing business portfolio. Additionally, the company's earnings surpassed estimates for the fourth straight time, when it reported third-quarter 2018 results. Management remains confident about continuing this stellar performance ahead driven by improving market conditions, higher global demand, gains from U.S. tax reform and aforementioned initiatives.

  • Implied Volatility Surging for Hi-Crush (HCLP) Stock Options
    Business
    Zacks

    Implied Volatility Surging for Hi-Crush (HCLP) Stock Options

    Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

  • Under Armour Up 37% in a Year, Expansion Efforts Bode Well
    Business
    Zacks

    Under Armour Up 37% in a Year, Expansion Efforts Bode Well

    Factors Driving the Stock With rising consciousness for health and wellness, sports apparel makers are entering the business of fitness gadgets and other tracking platforms to attract customers. The acquisitions of MapMyFitness, Endomondo and MyFitnessPal are in tune with the company's strategy of expanding its reach in the fitness space. Further, management is impressed with the popularity of UA HOVR.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of OPRX earnings conference call or presentation 5-Nov-18 9:30pm GMT

    We expect our operating expenses to naturally increase over time as we pursue our growth plans and expand our operations to support a growing customer base and partner network. However, for the foreseeable future, we expect to see operating expense as a percentage of revenue continuing to decline, supporting improvement in profitability. This was evident in our strong third quarter where we achieved our second consecutive quarter of profitability.

  • BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know
    Business
    Zacks

    BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know

    Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. While many investors like to look for momentum in stocks, this can be very tough to define. Below, we take a look at BeiGene, Ltd. (BGNE), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

  • What Do Analysts Recommend for Pfizer ahead of Its Q4 Results?
    Business
    Market Realist

    What Do Analysts Recommend for Pfizer ahead of Its Q4 Results?

    Analysts' Ratings for Pfizer Are Mixed ahead of Its Q4 ResultsAnalysts' recommendations Pfizer (PFE) is expected to post its earnings results for the fourth quarter of 2018 on January 29, 2019. Before we discuss the company's fourth-quarter

  • Whirlpool (WHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Business
    Zacks

    Whirlpool (WHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    The market expects Whirlpool (WHR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on January 28, 2019, might help the stock move higher if these key numbers are better than expectations.

  • Halliburton Plans Spending Cut As Earnings Drop Amid Shale Slowdown
    Business
    Investor's Business Daily

    Halliburton Plans Spending Cut As Earnings Drop Amid Shale Slowdown

    Halliburton stock fell slightly as crude oil prices pulled back. Halliburton Earnings Estimates: Analysts expected Halliburton earnings to fall 32% to 37 cents per share, according to Zacks Investment Research. Revenue is seen dipping $5.89 billion.

  • Business
    Markit

    See what the IHS Markit Score report has to say about ONEOK Inc.

    NYSE:OKE Summary Perception of the company's creditworthiness is negative ETFs holding this stock are seeing positive inflows but are weakening Bearish sentiment is low Economic output in this company's sector is contracting Short interest | Positive Short interest is low for OKE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETF/Index ownership | Negative ETF activity is negative and may be weakening.

  • What's in Store for Synchrony Financial's (SYF) Q4 Earnings?
    Business
    Zacks

    What's in Store for Synchrony Financial's (SYF) Q4 Earnings?

    Synchrony Financial SYF will release fourth-quarter 2018 results on Jan 23, 2019, before the market opens. In the last reported quarter, the company delivered a positive earnings surprise of 13.7%, backed by better strong loan receivables growth and purchase volume. The Zacks Consensus Estimate for earnings is pegged at 93 cents, up 32.9% year over year.

  • Business
    Markit

    See what the IHS Markit Score report has to say about Akorn Inc.

    NASDAQ/NGS:AKRX Summary ETFs holding this stock are seeing positive inflows but are weakening Bearish sentiment is low Short interest | Positive Short interest is low for AKRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETF/Index ownership | Negative ETF activity is negative and may be weakening.

  • Wynn Resorts (WYNN) Expected to Beat Earnings Estimates: Should You Buy?
    Business
    Zacks

    Wynn Resorts (WYNN) Expected to Beat Earnings Estimates: Should You Buy?

    Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change.